Pfizer Says Data Monitoring Committe Determined Phase 3 Trial Of IBRANCE Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer Is Unlikely To Show Statistically Significant Improvement In Primary Endpoint
Benzinga Newsdesk